Ernexa Therapeutics says it plans to file its application with the U.S. Food and Drug Administration in the third quarter of 2026 and dose its first patient with ERNA-101 in the fourth. The Cambridge, Massachusetts company laid out the schedule in a June 17 update.
ERNA-101 is a cell therapy. Ernexa builds it from induced pluripotent stem cells, turns them into mesenchymal stem cells, and engineers those to travel to tumors and release an IL-7/IL-15 fusion cytokine on arrival. The target is the so-called cold tumor, one that hides from the immune system and often ignores existing drugs. The company’s first aim is platinum-resistant ovarian cancer.
Where the work stands
Manufacturing process development is finished, and production under good manufacturing practice, the grade needed to supply a clinical trial, has started. Ernexa has also begun technology transfer to support larger-scale manufacturing and is still working through the studies and paperwork that must accompany its Investigational New Drug (IND) filing. It already held a pre-IND meeting with the FDA.
“With GMP manufacturing underway, technology transfer activities progressing and our IND submission expected in the third quarter of 2026, we believe we are entering one of the most important periods in the Company’s history,” said CEO Sanjeev Luther.
What the animal data show
The company points to preclinical work combining ERNA-101 with PD-1 blockade. It reports that detectable tumors disappeared entirely and that every animal survived through the follow-up period. Tumors also changed character, according to Ernexa, from suppressing the immune system to activating it, with more CD4+ and CD8+ T cells moving in. A March update described the same pairing in an ovarian cancer model, where it did far better than either agent alone.
None of this has been tested in people. Ernexa itself says the plan depends on the IND going through, and the filing carries the usual risk of delay.
Money and timeline
A recent $10.5 million financing, the company says, should cover the next 12 to 18 months. That period would take in the IND review, enrollment of the first ovarian cancer patient and, if all goes to plan, early clinical readouts in the first half of 2027. A move into Phase 2 with a possible co-development partner is pencilled in for the second half of that year.
Ernexa has a second program in the pipeline, ERNA-201, an anti-inflammatory cell therapy for autoimmune disease. Its own pre-IND meeting with the FDA is expected in the fourth quarter.
Sources
- Ernexa Therapeutics Advances ERNA-101 Towards First-in-Human Trials as Manufacturing and Regulatory Milestones are Achieved | ERNA Stock News
- Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA | ERNA Stock News
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
